Folate receptor-targeted aminopterin therapy is highly effective and specific in experimental models of autoimmune uveitis and autoimmune encephalomyelitis

Clinical Immunology

Volumn 150, Issue 1, 2014, Pages 64-77

  Lu, Yingjuan ^a   Wollak, Kristin N ^a   Cross, Vicky A ^a   Westrick, Elaine ^a   Wheeler, Leroy W ^a   Stinnette, Torian W ^a   Vaughn, Jeremy F ^a   Hahn, Spencer J ^a   Xu, Le Cun ^a   Vlahov, Iontcho R ^a   Leamon, Christopher P ^a  

^a Endocyte Inc   (United States)

Author keywords

Aminopterin; ; Anti inflammatory therapy; ; Autoimmune encephalomyelitis; Autoimmune uveitis; ; EC0746; ; Folate receptor;

Indexed keywords

AMINOPTERIN; EC 0746; EC 0923; ETARFOLATIDE TC 99M; FOLATE RECEPTOR; MYELIN BASIC PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE UVEITIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE SEVERITY; EXPERIMENTAL MODEL; FEMALE; MACROPHAGE; NONHUMAN; PARAMETERS; PRIORITY JOURNAL; RADIOGRAPHY; RAT;

AMINOPTERIN;; ANTI-INFLAMMATORY THERAPY;; AUTOIMMUNE ENCEPHALOMYELITIS; AUTOIMMUNE UVEITIS;; EC0746;; FOLATE RECEPTOR;;

AMINOPTERIN; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FOLATE RECEPTOR 2; FOLIC ACID ANTAGONISTS; MACROPHAGES; RATS; RATS, INBRED LEW; SPINAL CORD; UVEITIS;

EID: 84890018148     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.10.010     Document Type: Article

References (65)

1. Ifergan I., Assaraf Y.G. Molecular mechanisms of adaptation to folate deficiency. Vitam. Horm. 2008, 79:99-143.
2. Stover P.J., Field M.S. Trafficking of intracellular folates. Adv. Nutr. 2011, 2:325-331.
3. Zhao R., Diop-Bove N., Visentin M., Goldman I.D. Mechanisms of membrane transport of folates into cells and across epithelia. Annu. Rev. Nutr. 2011, 31:177-201.
4. Desmoulin S.K., Hou Z., Gangjee A., Matherly L.H. The human proton-coupled folate transporter: biology and therapeutic applications to cancer. Cancer Biol. Ther. 2012, 13:1355-1373.
5. Wang H., Ross J.F., Ratnam M. Structure and regulation of a polymorphic gene encoding folate receptor type gamma/gamma'. Nucleic Acids Res. 1998, 26:2132-2142.
6. Antony A.C. Folate receptors. Annu. Rev. Nutr. 1996, 16:501-521.
7. Elnakat H., Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv. Drug Deliv. Rev. 2004, 56:1067-1084.
8. Parker N., Turk M.J., Westrick E., Lewis J.D., Low P.S., Leamon C.P. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal. Biochem. 2005, 338:284-293.
9. Yamaguchi T., Hirota K., Nagahama K., Ohkawa K., Takahashi T., Nomura T., Sakaguchi S. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007, 27:145-159.
10. Kunisawa J., Hashimoto E., Ishikawa I., Kiyono H. A pivotal role of vitamin B9 in the maintenance of regulatory T cells in vitro and in vivo. PLoS One 2012, 7:e32094.
11. Kinoshita M., Kayama H., Kusu T., Yamaguchi T., Kunisawa J., Kiyono H., Sakaguchi S., Takeda K. Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon. J. Immunol. 2012, 189:2869-2878.
12. van der Heijden J.W., Oerlemans R., Dijkmans B.A., Qi H., van der Laken C.J., Lems W.F., Jackman A.L., Kraan M.C., Tak P.P., Ratnam M., Jansen G. Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis Rheum. 2009, 60:12-21.
13. Tsuneyoshi Y., Tanaka M., Nagai T., Sunahara N., Matsuda T., Sonoda T., Ijiri K., Komiya S., Matsuyama T. Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles. Scand. J. Rheumatol. 2012, 41:132-140.
14. Jager N.A., Teteloshvili N., Zeebregts C.J., Westra J., Bijl M. Macrophage folate receptor-beta (FR-beta) expression in auto-immune inflammatory rheumatic diseases: a forthcoming marker for cardiovascular risk?. Autoimmun. Rev. 2012, 11:621-626.
15. Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T., Tsukano M., Ratnam M., Matsuyama T. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1999, 42:1609-1616.
16. Nagayoshi R., Nagai T., Matsushita K., Sato K., Sunahara N., Matsuda T., Nakamura T., Komiya S., Onda M., Matsuyama T. Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages. Arthritis Rheum. 2005, 52:2666-2675.
17. Xia W., Hilgenbrink A.R., Matteson E.L., Lockwood M.B., Cheng J.X., Low P.S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009, 113:438-446.
18. Lu Y., Leamon C. Targeting activated macrophages via a functional folate receptor for potential treatment of autoimmune/inflammatory disorders. Targeted Drug Strategies for Cancer and Inflammation 2011, 195-216. Springer, New York. A.L. Jackman, C.P. Leamon (Eds.).
19. Nagai T., Tanaka M., Tsuneyoshi Y., Matsushita K., Sunahara N., Matsuda T., Yoshida H., Komiya S., Onda M., Matsuyama T. In vitro and in vivo efficacy of a recombinant immunotoxin against folate receptor beta on the activation and proliferation of rheumatoid arthritis synovial cells. Arthritis Rheum. 2006, 54:3126-3134.
20. Hansen M., Low P. Folate receptor positive macrophages: cellular targets for imaging and therapy of inflammatory and autoimmune diseases. Targeted Drug Strategies for Cancer and Inflammation 2011, 181-193. Springer, New York. A.L. Jackman, C.P. Leamon (Eds.).
21. Thomas T.P., Goonewardena S.N., Majoros I.J., Kotlyar A., Cao Z., Leroueil P.R., Baker J.R. Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum. 2011, 63:2671-2680.
22. Turk M.J., Breur G.J., Widmer W.R., Paulos C.M., Xu L.C., Grote L.A., Low P.S. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. 2002, 46:1947-1955.
23. Matteson E.L., Lowe V.J., Prendergast F.G., Crowson C.S., Moder K.G., Morgenstern D.E., Messmann R.A., Low P.S. Assessment of disease activity in rheumatoid arthritis using a novel folate targeted radiopharmaceutical Folatescan. Clin. Exp. Rheumatol. 2009, 27:253-259.
24. Ayala-Lopez W., Xia W., Varghese B., Low P.S. Imaging of atherosclerosis in apoliprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages. J. Nucl. Med. 2010, 51:768-774.
25. Farber S., Diamond L.K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N. Engl. J. Med. 1948, 238:787-793.
26. Rees R.B., Bennett J.H., Hamlin E.M., Maibach H.I. Aminopterin for psoriasis. A decade's observation. Arch. Dermatol. 1964, 90:544-552.
27. Weinstein G.D. Commentary: three decades of folic acid antagonists in dermatology. Arch. Dermatol. 1983, 119:525-527.
28. J.A. Zebala, Aminopterin dosage forms and methods for inflammatory disorders, US Patent 7,312,217, 2007.
29. Bertino J.R., Booth B.A., Bieber A.L., Cashmore A., Sartorelli A.C. Studies on the inhibition of dihydrofolate reductase by the folate antagonists. J. Biol. Chem. 1964, 239:479-485.
30. Cole P.D., Zebala J.A., Alcaraz M.J., Smith A.K., Tan J., Kamen B.A. Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy. Cancer Chemother. Pharmacol. 2006, 57:826-834.
31. Menter A., Thrash B., Cherian C., Matherly L.H., Wang L., Gangjee A., Morgan J.R., Maeda D.Y., Schuler A.D., Kahn S.J., Zebala J.A. Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter. J. Pharmacol. Exp. Ther. 2012, 342:696-708.
32. Vlahov I.R., You F., Santhapuram H.K., Wang Y., Vaughn J.F., Hahn S.J., Kleindl P.J., Fan M., Leamon C.P. Design and regioselective synthesis of a new generation of targeted therapeutics. Part 3: Folate conjugates of aminopterin hydrazide for the treatment of inflammation. Bioorg. Med. Chem. Lett. 2011, 21:1202-1205.
33. Lu Y., Stinnette T.W., Westrick E., Klein P.J., Gehrke M.A., Cross V.A., Vlahov I.R., Low P.S., Leamon C.P. Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate. Arthritis Res. Ther. 2011, 13:R56.
34. Murray P.I., Sivaraj R.R. Anti-TNF-alpha therapy for uveitis: Behcet and beyond. Eye (Lond) 2005, 19:831-833.
35. Larson T., Nussenblatt R.B., Sen H.N. Emerging drugs for uveitis. Expert Opin. Emerg. Drugs 2011, 16:309-322.
36. Dhib-Jalbut S. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Neurology 2007, 68:S13-S21. (discussion S43-54).
37. Sharief M.K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991, 325:467-472.
38. Bruck W., Sommermeier N., Bergmann M., Zettl U., Goebel H.H., Kretzschmar H.A., Lassmann H. Macrophages in multiple sclerosis. Immunobiology 1996, 195:588-600.
39. Beckmann N., Cannet C., Babin A.L., Ble F.X., Zurbruegg S., Kneuer R., Dousset V. In vivo visualization of macrophage infiltration and activity in inflammation using magnetic resonance imaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1:272-298.
40. Khera T.K., Copland D.A., Boldison J., Lait P.J., Szymkowski D.E., Dick A.D., Nicholson L.B. Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. Clin. Exp. Immunol. 2012, 168:165-177.
41. Vlahov I.R., Santhapuram H.K., You F., Wang Y., Kleindl P.J., Hahn S.J., Vaughn J.F., Reno D.S., Leamon C.P. Carbohydrate-based synthetic approach to control toxicity profiles of folate-drug conjugates. J. Org. Chem. 2010, 75:3685-3691.
42. Leamon C.P., Parker M.A., Vlahov I.R., Xu L.C., Reddy J.A., Vetzel M., Douglas N. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug. Chem. 2002, 13:1200-1210.
43. Leamon C.P., Reddy J.A., Dorton R., Bloomfield A., Emsweller K., Parker N., Westrick E. Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates. J. Pharmacol. Exp. Ther. 2008, 327:918-925.
44. Diedrichs-Mohring M., Hoffmann C., Wildner G. Antigen-dependent monophasic or recurrent autoimmune uveitis in rats. Int. Immunol. 2008, 20:365-374.
45. Hou W., Wu Y., Sun S., Shi M., Sun Y., Yang C., Pei G., Gu Y., Zhong C., Sun B. Pertussis toxin enhances Th1 responses by stimulation of dendritic cells. J. Immunol. 2003, 170:1728-1736.
46. Mannie M., Swanborg R.H., Stepaniak J.A. Experimental autoimmune encephalomyelitis in the rat. Curr. Protoc. Immunol. 2009, (Suppl. 85):15.2.1-15.2.15.
47. Shooshtari P., Fortuno E.S., Blimkie D., Yu M., Gupta A., Kollmann T.R., Brinkman R.R. Correlation analysis of intracellular and secreted cytokines via the generalized integrated mean fluorescence intensity. Cytometry A 2010, 77:873-880.
48. Li C., Takahashi C., Zhang L., Huseni M., Stankovich B., Mashhedi H., Lee J., French D., Anderson J.E., Kim D., Howell K., Brauer M.J., Kowanetz M., Yan Y., Humke E., Ebens A., Hampton G., Lackner M.R., Hegde P., Jia S. Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma. J. Transl. Med. 2013, 11:76.
49. Huitinga I., Ruuls S.R., Jung S., Van Rooijen N., Hartung H.P., Dijkstra C.D. Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin. Exp. Immunol. 1995, 100:344-351.
50. Teng L., Xie J., Lee R.J. Clinical translation of folate receptor-targeted therapeutics. Expert Opin. Drug Deliv. 2012, 9:901-908.
51. Birn H. The kidney in vitamin B12 and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins. Am. J. Physiol. Renal Physiol. 2006, 291:F22-F36.
52. Steinbrecher A., Weber T., Neuberger T., Mueller A.M., Pedre X., Giegerich G., Bogdahn U., Jakob P., Haase A., Faber C. Experimental autoimmune encephalomyelitis in the rat spinal cord: lesion detection with high-resolution MR microscopy at 17.6T. AJNR Am. J. Neuroradiol. 2005, 26:19-25.
53. Abourbeh G., The'ze' B., Maroy R., Dubois A., Brulon V., Fontyn Y., DolleD́ F., Tavitian B., Boisgard R. Imaging microglial/macrophage activation in spinal cords of experimental autoimmune encephalomyelitis rats by positron emission tomography using the mitochondrial 18kDa translocator protein radioligand [18F]DPA-714, The. J. Neurosci. 2012, 32:5728-5736.
54. Nagai T., Kyo A., Hasui K., Takao S., Matsuyama T. Efficacy of an immunotoxin to folate receptor beta in the intra-articular treatment of antigen-induced arthritis. Arthritis Res. Ther. 2012, 14:R106.
55. Guillemin G.J., Brew B.J. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol. 2004, 75:388-397.
56. Boster A., Edan G., Frohman E., Javed A., Stuve O., Tselis A., Weiner H., Weinstock-Guttman B., Khan O. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008, 7:173-183.
57. Neri P., Zucchi M., Allegri P., Lettieri M., Mariotti C., Giovannini A. Adalimumab (Humira()): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology. Int. Ophthalmol. 2011, 31:165-173.
58. Sicotte N.L., Voskuhl R.R. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001, 57:1885-1888.
59. Wildner G., Diedrichs-Mohring M., Thurau S.R. Rat models of autoimmune uveitis. Ophthalmic Res. 2008, 40:141-144.
60. Schmitt C., Strazielle N., Ghersi-Egea J.F. Brain leukocyte infiltration initiated by peripheral inflammation or experimental autoimmune encephalomyelitis occurs through pathways connected to the CSF-filled compartments of the forebrain and midbrain. J. Neuroinflammation 2012, 9:187.
61. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 2012, 122:787-795.
62. Leamon C.P., Reddy J.A., Vlahov I.R., Westrick E., Dawson A., Dorton R., Vetzel M., Santhapuram H.K., Wang Y. Preclinical antitumor activity of a novel folate-targeted dual drug conjugate. Mol. Pharm. 2007, 4:659-667.
63. Reddy J.A., Dorton R., Westrick E., Dawson A., Smith T., Xu L.C., Vetzel M., Kleindl P., Vlahov I.R., Leamon C.P. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res. 2007, 67:4434-4442.
64. Tian Y., Wu G., Xing J.C., Tang J., Zhang Y., Huang Z.M., Jia Z.C., Zhao R., Tian Z.Q., Wang S.F., Chen X.L., Wang L., Wu Y.Z., Ni B. A novel splice variant of folate receptor 4 predominantly expressed in regulatory T cells. BMC Immunol. 2012, 13:30.
65. Reddy J.A., Haneline L.S., Srour E.F., Antony A.C., Clapp D.W., Low P.S. Expression and functional characterization of the beta-isoform of the folate receptor on CD34(+) cells. Blood 1999, 93:3940-3948.